BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]
GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]
Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company. Read the full article: https://www.biotech-finances.com/126504-2/ Contact us to get more information:
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]
We took part in the event “Anchoring Clinical Research in Belgium” jointly organized by BioWin and flanders.bio in Brussels where we had an interesting debate on funding opportunities for biomedical research and clinical trials development in a sector where Belgium is leading globally. Thank you to Bone Therapeutics, icometrix and Ayming Belgium for sharing the stage. […]
There is no excerpt because this is a protected post.
A new article about our customer PDC*line Pharma published in the newspaper L’Echo: with an interview of President & CEO Eric Halioua underlining the achievements made by the company over the last 4 years. Source: https://www.lecho.be/entreprises/pharma-biotechnologie/PDC-line-Pharma-nouvel-espoir-wallon-contre-le-cancer/10191614
Our customer Imcyse is announcing to the world their excellent first-in-human clinical results in Type 1 Diabetes. Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098
Proud to have helped Imcyse to fundraise 35M€ to carry out clinical trials of treatments for type 1 diabetes, multiple sclerosis and other autoimmune diseases. Please read the article in L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/imcyse-se-profile-comme-la-future-pepite-wallonne-de-la-biotech/10137301.html Imcyse secures total of €35M in Series B financing round and additional grants
We are present at BioWinConnect 2018 to get last updates about incubation models and collaboration that could enforce our startup studio.
B.R.A.I.N. hub (Belgian Research And Innovation in Neurosciences), the second European Human Brain Project’s National Hub for Innovation (HBP-NHI-be), was successfully launched in Belgium thanks to the initiative of Abaxys Therapeutics and our startupstudio.be. Press release: https://gallery.mailchimp.com/86270bb6b0c29cba9301c4907/files/d77b9722-7fd0-4679-9ef4-18cd08f24a6f/BRAINhub_kick_off_press_release_HBP_NHI_be_Mar_2019.pdf?mc_cid=27e3a48b74&mc_eid=6d7be67224
New success story for our customer PDC*line Pharma which enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia. PDC*line Pharma enters into licensing agreement with LG Chem to develop PDC*lung cancer vaccine in Asia
Proud to have supported a third of the biotech companies which are representing Belgium at BIO-Europe 2017 in Berlin, Europe’s largest life science partnering conference.
Our customer Univercells has been awarded a $12 Million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform. Its aim is to drastically reduce the cost of vaccines whilst increasing their availability and affordability in developing countries. « Humanity’s greatest advances are not in its discoveries, but in how those discoveries[…]
Our customer Univercells partners with Takeda Pharmaceutical Company Limited to produce affordable vaccines for All. Press release: http://www.univercells.com/newsroom/univercells-partners-takeda/
Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis’ product and will also maintain his CDMO core business activity in[…]